Turn Therapeutics (TTRX) Net Income towards Common Stockholders (2024 - 2026)
Turn Therapeutics' (TTRX) quarterly Net Income towards Common Stockholders came in at -$3.1 million in Q1 2026, down 449.34% year-on-year from $900696.3 in Q1 2025, and down 7.5% quarter-over-quarter from -$2.9 million in Q4 2025.
Turn Therapeutics (TTRX) Net Income towards Common Stockholders (2024 - 2026) Analysis & Trends
Turn Therapeutics' Net Income towards Common Stockholders history runs 3 years deep, the most recent figure standing at -$3.1 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 449.34% year-over-year to -$3.1 million in Q1 2026; TTM through Mar 2026 was -$14.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$13.9 million, down 146.3% from the prior year.
- Net Income towards Common Stockholders eased to -$3.1 million in Q1 2026 per TTRX's latest filing, from -$2.9 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$470237.0 in Q4 2024 and bottomed at -$7.6 million in Q3 2025.
- The 3-year median for Net Income towards Common Stockholders is -$2.0 million (2024), against an average of -$2.6 million.
- Across the five-year window, Net Income towards Common Stockholders sank 638.58% in 2025 and tumbled 449.34% in 2026, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$470237.0 in 2024, then sank by 522.47% to -$2.9 million in 2025, then fell by 7.5% to -$3.1 million in 2026.
- Per Business Quant, the three latest TTRX Net Income towards Common Stockholders figures stand at -$3.1 million (Q1 2026), -$2.9 million (Q4 2025), and -$7.6 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,924.26 Bn | 1,924.20 Bn | - | - |
| 3 | Akari Therapeutics | 975.59 Bn | 975.59 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.47 Bn | 466.67 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.76 Bn | 114.52 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.15 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.83 Bn | 62.83 Bn | - | -0.68 |
| 8 | Argenx Se | 55.77 Bn | 50.59 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.45 Bn | 37.45 Bn | - | -453.82 Mn |
| 10 | Turn Therapeutics | 233.89 Mn | 233.89 Mn | - | -3.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.15 Mn |
| Dec 31, 2025 | -2.93 Mn |
| Sep 30, 2025 | -7.58 Mn |
| Mar 31, 2025 | -572,775.00 |
| Dec 31, 2024 | -470,237.00 |
| Sep 30, 2024 | -1.03 Mn |